硼替佐米联合替莫唑胺与区域放疗用于新诊断多形性胶质母细胞瘤一线治疗的2期研究:安全性与疗效评估
24例新诊断多形性胶质母细胞瘤患者接受标准区域放疗联合同步替莫唑胺,并联合硼替佐米(放疗期间1.3 mg/m2于第1、4、8、11、29、32、36、39天给药,放疗后每4周第1、4、8、11天给药),随后辅助替莫唑胺和硼替佐米≤24周期。加用硼替佐米未出现意外不良事件,中位无进展生存期6.2个月,中位总生存期19.1个月,MGMT甲基化患者获益更多。作者认为需在更大队列中进一步临床研究。
要点
- 加用硼替佐米未出现意外不良事件,方案可耐受。
- 中位无进展生存期6.2个月,中位总生存期19.1个月。
- MGMT甲基化患者中位无进展生存期24.7个月,未甲基化患者5.1个月。
核心结论
- 在新诊断多形性胶质母细胞瘤患者中,于当前标准化放化疗基础上加用硼替佐米可耐受。
- 无进展生存率和总生存率似乎有前景,对MGMT甲基化患者获益更多。
- 作者认为需在更大患者队列中进一步临床研究。
研究设计与样本
- 2期研究,纳入24例新诊断多形性胶质母细胞瘤患者。
- 患者接受标准外照射区域放疗联合同步替莫唑胺,于术后3至6周开始,随后辅助替莫唑胺和硼替佐米≤24周期或直至肿瘤进展。
- 放疗期间硼替佐米1.3 mg/m2于第1、4、8、11、29、32、36、39天给药;放疗后硼替佐米1.3 mg/m2于每4周的第1、4、8、11天给药。
主要发现
- 加用硼替佐米未发生意外不良事件。
- 中位无进展生存期6.2个月(95%CI 3.7-8.8),18个月和24个月无进展生存率均为25.0%,30个月为16.7%。
- 中位总生存期19.1个月(95%CI 6.7-31.4),12个月总生存率87.5%,24个月50.0%,36至60个月34.1%。
- 10例MGMT甲基化患者中位无进展生存期24.7个月(95%CI 8.5-41.0),13例未甲基化患者5.1个月(95%CI 3.9-6.2)。
- MGMT甲基化患者估计中位总生存期61个月(95%CI上限未达到),未甲基化患者16.4个月(95%CI 11.8-21.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需在更大患者队列中进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for ≤24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: Twenty-four patients with newly diagnosed GBM were enrolled. The patients received standard external beam regional RT with concurrent TMZ beginning 3 to 6 weeks after surgery, followed by adjuvant TMZ and bortezomib for ≤24 cycles or until tumor progression. During RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, 11, 29, 32, 36, and 39. After RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, and 11 every 4 weeks. RESULTS: No unexpected adverse events occurred from the addition of bortezomib. The efficacy analysis showed a median progression-free survival (PFS) of 6.2 months (95% confidence interval [CI] 3.7-8.8), with promising PFS rates at ≥18 months compared with historical norms (25.0% at 18 and 24 months; 16.7% at 30 months). In terms of overall survival (OS), the median OS was 19.1 months (95% CI 6.7-31.4), with improved OS rates at ≥12 months (87.5% at 12, 50.0% at 24, 34.1% at 36-60 months) compared with the historical norms. The median PFS was 24.7 months (95% CI 8.5-41.0) in 10 MGMT methylated and 5.1 months (95% CI 3.9-6.2) in 13 unmethylated patients. The estimated median OS was 61 months (95% CI upper bound not reached) in the methylated and 16.4 months (95% CI 11.8-21.0) in the unmethylated patients. CONCLUSIONS: The addition of bortezomib to current standard radiochemotherapy in newly diagnosed GBM patients was tolerable. The PFS and OS rates appeared promising, with more benefit to MGMT methylated patients. Further clinical investigation is warranted in a larger cohort of patients.
引用
- Kong XT, Nguyen NT, Choi YJ, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722661. doi:10.1016/j.ijrobp.2018.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。